Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of emactuzumab versus placebo in tenosynovial giant cell tumour
NL-OMON51288Phase 3Not yet recruiting
- Sponsor
- SynOx Therapeutics
- Start
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in tenosynovial giant cell tumor (TGCT) comparing Emactuzumab with Placebo (2 arms). Primary endpoint: Objective response rate by 6 months. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
emactuzumab
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on NL-OMON51288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51288.